EXPIRED
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
NIDA Research Center of Excellence Grant Program (P50)
P50 Specialized Center
Reissue of PAR-13-222
PAR-16-009
None
93.279
This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDA’s mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.
October 21, 2015
New Date December 7, 2015 per issuance of NOT-DA-16-002. (Original Date: August 25, 2016 )
30 days prior to the application due date
Any due dates on or after Jan 25, 2018 must use reissued FOA.
September 25, 2016; September 25, 2017; September 25, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
January 7, 2016; January 7, 2017; January 7, 2018; January 7, 2019 by 5:00 PM local time of applicant organization.
All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
March 2016, March 2017, March 2018, March 2019
May 2016, May 2017, May 2018, May 2019
July 2016, July 2017, July 2018, July 2019
Not Applicable
NIH’s new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. Applications to this FOA must be submitted electronically; paper applications will not be accepted. ASSIST replaces the Grants.gov downloadable forms currently used with most NIH opportunities and provides many features to enable electronic multi-project application submission and improve data quality, including: pre-population of organization and PD/PI data, pre-submission validation of many agency business rules and the generation of data summaries in the application image used for review.
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts) and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section
I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
NIDA supports research center grants to foster an innovative, synergistic and thematically coherent approach to drug abuse and addiction research and to enable studies that would not occur without the climate, facilities and/or interactive research resources that a research center can uniquely provide. NIDA encourages the application of multiple scientific perspectives and approaches to the problem of addiction to support the highest quality, multidisciplinary programs of innovative research. Through the Centers program, NIDA seeks to encourage outstanding scientists to bring a full range of expertise, approaches, technologies, and creativity to the study of problems related to drug abuse and addiction. Investigative efforts are expected to be broadly based and to encompass a variety of areas, including biological, biomedical, social, behavioral, and/or clinical sciences as well as dissemination sciences to address critical research issues.
NIDA Centers are expected to be scientifically innovative and provide the next generation of ideas and approaches. It is expected that a Center will transform knowledge in the sciences it is studying and be at the cutting edge of science. Incremental work, though valuable, should not be the focus of Center activities.
NIDA Centers are expected to be thematically coherent and demonstrate the highest caliber of multidisciplinary scientific work; there must be an overarching theme that integrates and focuses the Center. Each core and research component should relate to the overall Center theme and to other components of the Center to provide a synergy that leads to creative thinking, novel approaches, innovations, and highly significant findings. Interactions and integration of projects should be clearly evident, so that the Center does not appear to be a collection of independent research projects. There should be linkages among components that result in levels of productivity, quality, and progress that will exceed those expected from combining the individual components in an additive fashion. Linkages may be conceptual, spatial, and/or temporal. Interdependency of the scientific projects may allow for a variety of arrangements, for example, multiple research components sharing a common subject pool managed through a core or a common imaging protocol managed in a core to allow for comparability of data across research projects. The type of integration proposed may be different for different genres of science, including: conceptual integration or sharing of data, instruments, and other resources. Linkages should encourage cross-fertilization of ideas and interactions among investigators that are relevant to the theme. Multidisciplinary research activity is expected across a variety of disciplines or sub-disciplines to bring multiple scientific perspectives and approaches to a research area or question.
In addition, NIDA Research Centers are expected to serve as national research resources in the drug abuse research field to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. They are expected to attract established and promising investigators into drug abuse research. The P50 Center application is expected to foster the career development and mentoring of new investigators and provide opportunities for effective dissemination of research findings.
HIV/AIDS Counseling and Testing Policy for the National Institute on Drug Abuse: In light of recent significant advances in rapid testing for HIV and in effective treatments for HIV, NIDA has revised its 2001 policy on HIV counseling and testing. NIDA-funded researchers are strongly encouraged to provide and/or refer research subjects to HIV risk reduction education and education about the benefits of HIV treatment, counseling and testing, referral to treatment, and other appropriate interventions to prevent acquisition and transmission of HIV. This policy applies to all NIDA funded research conducted domestically or internationally. For more information see https://grants.nih.gov/grants/guide/notice-files/NOT-DA-07-013.html
National Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Subjects: The National Advisory Council on Drug Abuse (NACDA) recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects. Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. For more information see http://www.drugabuse.gov/funding/clinical-research/nacda-guidelines-administration-drugs-to-human-subjects
Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants: The National Advisory Council on Drug Abuse (NACDA) encourages NIDA and its grantees to consider the points it has set forth with regard to existing or prospective sponsored research agreements with tobacco companies or their related entities and the impact of acceptance of tobacco industry funding on NIDA's credibility and reputation within the scientific community. For more information see http://www.drugabuse.gov/about-nida/advisory-boards-groups/national-advisory-council-drug-abuse-nacda/council-statements/points-to-consider-regarding-tobacco-industry-funding-nida
Data Harmonization for Substance Abuse and Addiction via the PhenX Toolkit: NIDA strongly encourages investigators involved in human-subjects studies to employ a common set of tools and resources that will promote the collection of comparable data across studies and to do so by incorporating the measures from the Core and Specialty collections, which are available in the Substance Abuse and Addiction Collection of the PhenX Toolkit (www.phenxtoolkit.org). For more information see https://grants.nih.gov/grants/guide/notice-files/NOT-DA-12-008.html.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
New
Renewal - a Center may be funded for a maximum of two competitive segments
Resubmission
Revision
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Clinical Trials Not Allowed for due dates on or after January 25, 2018: Only accepting applications that do not propose clinical trials
Need help determining whether you are doing a clinical trial?
The number of awards is contingent upon NIH appropriations and the submission of meritorious applications.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
In general, renewal grants should not increase by more than 10% over the prior year’s award. For more information see http://www.drugabuse.gov/funding/funding-priorities/nida-funding-strategy/nida-funding-strategy-fiscal-year-2015).
Applicants may apply for up to five years of support.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Governments
Other
Non-domestic (non-U.S.) Entities (Foreign Institutions) are
not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible
to apply.
Foreign components, as defined in
the NIH Grants Policy Statement, are not allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
For purposes of this FOA, the Program Director/Principal Investigator (PD/PI) will be referred to as the Center Director.
An individual who serves as the Center Director of a NIDA P50 Center grant may not concurrently serve as the PD/PI of another NIDA-supported Center. It is expected that the Center Director will commit at least 2.4 person months to Center administration including the administrative core and 1.8 person months to any other core and/or research component directly supported by the Center grant, for a minimum total of 4.2 person months effort.
When multiple Center Directors are proposed, each one is expected to commit a minimum of 2.4 person months effort.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
Following 2 funded competitive segments, NIDA will accept a new application that is a significant and substantial change in concept and scope when compared to the previously funded renewal. Applicants are strongly encouraged to contact their Program Officer at least 6 months before the application due date to discuss the new concepts and to discuss submission as a new NIDA P50 Center. Investigators and their institutions are expected to follow these guidelines so institutions can submit applications that are eligible to advance in the review process.
Revisions: Applications for Revisions to Center grants will be supported only under the most exceptional circumstances. Revision applications are expected to meet all criteria for a NIDA Center listed above and are expected to contribute to the overall theme of the Center and be clearly linked to other ongoing Center Research Projects in a synergistic fashion. NIDA encourages applicants to consult with NIDA prior to submission of a revision application.
U54 or P50 center grants that have not already had two competitive segments of center grant funding may apply to this FOA for a second competitive segment.
Applicants can access the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
Most applicants will use NIH’s ASSIST system to prepare and submit applications through Grants.gov to NIH. Applications prepared and submitted using applicant systems capable of submitting electronic multi-project applications to Grants.gov will also be accepted.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to: [email protected]
If preferred, hard copy (paper) letters may be sent to:
Office of Extramural Policy and Review
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Boulevard, Room 4243, MSC 9550
Bethesda, MD 20892
Component Types Available in ASSIST |
Research Strategy/Program Plan Page Limits |
Overall |
12 |
Admin Core |
6 |
Core (use for Research Core Pilot Project Core) |
12 |
Project (use for Research Projects) |
12 |
Additional page limits described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application.
Revision applications must include an Overall component and the components that are affected by the revision. Therefore, the component requirements listed below may not apply to the revision application.
The application should consist of the following components:
When preparing your application in ASSIST, use Component Type Overall .
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Complete entire form.
Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.
Follow standard instructions, as well as the following additional instructions
Facilities & Other Resources: The application should document availability of appropriate and adequate facilities dedicated to the conduct of administrative, shared resource, and research activities. While all members of the Center need not be located physically in facilities controlled exclusively by the Center, there must be a clearly identifiable physical location which insures adequate administrative oversight for the Center and associated core units that are providing shared resources. Describe the types and quality of shared laboratory and clinical facilities.
Other Attachments: The following information should be loaded as separate PDF attachments. The filename provided for each attachment will be the name used for the bookmark in the application image.
Center Organizational Structure. Applicants should include a diagram of the organizational structure of the Center. This diagram should demonstrate how the interactions among the Center components will achieve the stated goals of the Center. The diagram should be attached as a PDF, titled "Center_Organizational_Structure".
Table of Research Core Utilization. In order to assist the reviewers in determining the relationship between the Research Cores and the Research Projects, a table should be provided that indicates the percentage use of each core relative to the individual projects. The table should be attached as a PDF, titled "Table_of_Research_Core_Utilization". This table is only required if there are Research Cores.
Enter primary site only.
A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.
Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.
A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.
The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.
A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is required in the Overall component.
Specific Aims: Specific Aims are required.
Research Strategy: NIDA now limits Centers to a maximum of two competitive segments, each for a maximum of 5 years of support. All applications for NIDA Centers should include plans for orderly completion of the Center’s programs and projects within the 5-year project period.
Each Center application is expected to provide evidence of an environment that promotes the conduct of the highest quality, state-of-the-art research, innovation, and leadership in its areas of investigation. Applicants are expected to demonstrate that the Center is, or would serve as, a significant national scientific research resource soon after its establishment, to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers. For renewals, the application is expected to demonstrate its past success in doing so and how the Center will continue to serve as a national resource.
Much of the shared research environment and many facilities will be located in or funded through the core components. The Overall section should discuss how each core component contributes toward cost-effectiveness and quality control in resource utilization among the research components; how data analytic capacities, database facilities and data resources would be utilized among Center components.,
All NIDA Centers are expected to clearly demonstrate that they support innovative, rigorous, thematically focused, and productive research that is the result of interacting components of the research program that would not emerge from the mere collection of those individual components. A cadre of experienced, independent and productive investigators should be present with active collaborations in place or planned. These investigators should evidence productivity, stature and leadership, or a potentially strong leadership role, in their respective fields. A broad range of expertise relevant to the Center's goals should be present. Investigative efforts may encompass researchers with primary appointments at the applicant institution as well as at other collaborating sites. Investigators are expected to commit to data sharing and ongoing communications with other investigators in the Center, consistent with achieving the goals of the program.
Applications should explicitly discuss the integration of work proposed in the application. Further, applications should demonstrate that use of the research Center mechanism is essential to accomplishing studies that would not occur without the climate, facilities and research resources that a research Center can uniquely provide.
For Renewal Applications Only: Include a progress report including a summary of the most significant advances accomplished during the prior period of support. The Progress Report should demonstrate the research environment's conduciveness to productivity by identifying the originally approved specific aims, the progress made on each specific aim, and relevant publications produced in the previous funding period. It is especially important that renewals (1) identify innovative work accomplished by the Center during the current funding period and (2) propose innovative work for the new funding period. Changes in the Specific Aims, including termination of Research Components or Cores, should be described and justified and major findings presented with clear descriptions of the importance of these findings to advances in the field. The application should also address any significant organizational changes, and provide a summary of the career development opportunities and mentoring provided to junior investigators as well as results of education and dissemination activities. Centers that conduct clinical trials must also provide a summary of recruitment, retention, and safety issues, for each trial conducted.
Progress Report Publication List: Include also a Progress Report Publication List. Cite complete references to appropriate publications and manuscripts accepted for publication that resulted from the work during the prior funding period.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Admin Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Complete only the following fields:
Enter Human Embryonic Stem Cells in each relevant component.
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Budget forms appropriate for the specific component will be included in the application package. In developing the budget, applicants should take into account funds currently available through existing collaborating grants and explain how these funds might be reconfigured to maximize efficient resource utilization. The Center is intended to provide reasonable support for activities clearly related to the specialized research needs of the Center.
It is expected that the Center Director will commit at least 2.4 person months effort to Center administration including the Administrative Core.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: Specific Aims are required.
Research Strategy:
The Administrative Core is expected to have appropriate and effective administrative and organizational capabilities to support multidisciplinary research, to foster synergy, and to support planning and evaluation activities. Administrative and organizational arrangements should promote joint planning and evaluation activities as well as collaborations and interactions within, between and among programmatic elements of the center. This should include: (a) an overall programmatic structure that effectively promotes scientific interactions, provides for internal quality control of research and publications, generation of future grant applications, and also takes maximum advantage of the Center’s drug abuse research capability (the description of these attributes is particularly important when there are multiple participating institutions in the Center); (b) an administrative organization that has clear lines of authority, is managed efficiently and cost effectively, and enables effective use and leverage of resources; (c) the use of an external advisory structure that is charged to provide appropriate and objective advice and evaluation, as needed, to the Center Director; (d) an internal advisory, decision-making, and priority setting process to support the activities of the Center; and (e) appropriate criteria and processes for determining and sustaining individual participation in the Center based on productivity, research direction, and overall contribution.
Education Activities: As part of serving as a national resource, a NIDA P50 Center is expected to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers. Activities may include, but need not be limited to, conferences, seminars, webinars, workshops, newsletters, informational websites, or social media initiatives.
Letters of Support: There should be convincing evidence of the applicant institution's commitment to the Center.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan. NIDA Centers are supported both for their expected crucial scientific accomplishments and for their role as vital resources to the research community. In order to maximize the impact of their work, they are expected to make their data, their methodologies and their findings available in a timely manner to other researchers and those who have a legitimate purpose for the access. In most instances, the data sharing would extend beyond that of one's own Center to the research community. This sharing can be accomplished in many ways, including posting findings on the Center's website or using archival services. Data sharing plans are expected to be provided, consistent with achieving the goals of the program. A plan for development and dissemination of assessments and methodologies and a general publication plan are also expected.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Complete only the following fields:
PHS 398 Cover Page Supplement (Research Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Research Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Research Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Research Core)
Budget (Research Core)
Budget forms appropriate for the specific component will be included in the application package.
In developing the budget for a Research Core, applicants should take into account funds currently available through existing collaborating grants and explain how these funds might be reconfigured to maximize efficient resource utilization. The Center is intended to provide reasonable support for activities clearly related to the specialized research needs of the Center.
It is expected that the Core director will make a substantial commitment of time and effort to the Core, at least 1.8 person months effort to administrative and research-related activities directly supported by the Core.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Research Core)
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: Specific Aims are required.
Research Strategy: A Research Core can be a laboratory, a facility, a service, or other shared resource that supports other Center components in their activities. Research Cores are expected to support two or more Research Components and each Research Core should be clearly described in terms of the services and resources to be provided to other Center components. Issues to be addressed include: quality control, procedures for selecting projects that use the Core, cost effectiveness, and increased efficiency. User training in complex techniques and methods should be described if they are functions of the proposed cores. Core components are intended to enhance opportunities for investigators at the Center to include new technologies that broaden their research initiatives. While research per se is not an essential part of a scientific core, quality assurance activities that evaluate its operations and are directed at problem identification and improvement of core functioning are appropriate
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
A Pilot Project Core is permitted but individual pilot projects within a Pilot Project Core do not count toward the total number of Research Projects. At least three Research Projects must be active at all times.
SF424 (R&R) Cover (Pilot Project Core)
Complete only the following fields:
PHS 398 Cover Page Supplement (Pilot Project Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Pilot Project Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Pilot Project Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Pilot Project Core)
Budget (Pilot Project Core)
Budget forms appropriate for the specific component will be included in the application package.
In developing the budget for the Pilot Project Core, applicants should take into account funds currently available through existing collaborating grants and explain how these funds might be reconfigured to maximize efficient resource utilization. The Center is intended to provide reasonable support for activities clearly related to the specialized research needs of the Center.
Direct costs allocated to pilot projects in any year cannot exceed 25% of the Center grant’s total direct costs in that year or $200,000, whichever is smaller.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Pilot Project Core)
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: Specific Aims are required.
Research Strategy: Applicants may choose to include pilot projects in the Center, as a separate Core component. Pilot projects may be used for new, early stage or independent investigators and should represent new projects to develop and explore new activities or directions or take advantage of special opportunities. Pilot projects may be research and development pilots, feasibility studies, or other pilot work broadly defined as foundation work for further research. Pilot projects may not be used to supplement or prolong ongoing research and should not be used as bridge funds when other research support is no longer available.
The support of individual pilot project studies is typically of relatively short duration (e.g., 1-2 years), depending upon the nature of the research. Applicants may propose and request funding in the first year for specific, already conceptualized pilot projects and also for pilot projects to be added in subsequent years of the project. Applications requesting support for pilot projects must describe a process for within-Center scientific review of new pilot projects to be initiated in future years of the project and a process for evaluation of ongoing pilot projects for adequate progress. Pilot projects presented in the application will be reviewed as part of the assessment of scientific and technical merit of the application and as examples of the kinds of pilot projects the Center might initiate in the future as a result of its internal within-Center review process.
For all pilot projects, describe the internal institutional plans and procedures to ensure that all projects supported from this award will comply fully with all applicable Federal regulations, policies, and guidelines for research involving human subjects, including the evaluation of risks and protections in project proposals, appropriate ethical oversight and funded projects, and plans for data and safety monitoring for clinical trials, if applicable.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Project.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Research Projects)
Complete only the following fields:
PHS 398 Cover Page Supplement (Research Project)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Research Project)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Research Project)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Research Project)
Budget (Research Project)
Budget forms appropriate for the specific component will be included in the application package.
It is expected that the Research Project Director will make a substantial commitment of time and effort to the Center, at least 1.8 person months effort to research-related activities directly supported by the Research project
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Research Project)
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: Specific Aims are required.
Research Strategy: Research may focus on any area of NIDA's mission, but must bear an essential relationship to the Center’s integrating theme and efficiently use and contribute to Center resources. If applicable, the Research Strategy should describe how the Research Project will use Center Research Core facilities and how the Core resources impact the proposed project.
Career Development and Mentoring: While the primary function of each Center is the conduct of high-quality interdisciplinary research, an important secondary function is fostering the career development and mentoring of research and clinical personnel. Career development and mentoring to enhance junior researchers' or other researchers' skills should be conducted in the context of the research, and funds may not be used for training not required to conduct the research. However, Center staff may participate in the development of related training programs, and Center resources may be made available for use by students, postdoctorates, and new investigators seeking experience in drug abuse research. Centers are expected to recruit and nurture future generations of scientists to engage in drug abuse and addiction research, especially those from underrepresented backgrounds.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
See Part I. Section III.1 for information regarding the requirements for obtaining a Dun and Bradstreet Universal Numbering System (DUNS) Number and for completing and maintaining an active System for Award Management (SAM) registration. Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
For information on how your application will be automatically assembled for review and funding consideration after submission go to: https://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues.
Important reminders:
All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.
Applicants are required to follow our Post Submission Application Materials policy.
Important Update: See NOT-OD-16-006 and NOT-OD-16-011 for updated review language for applications for due dates on or after January 25, 2016.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the center to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the Center proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a Center that by its nature is not innovative may be essential to advance a field.
Does the Center address an important problem or a critical barrier to progress in the field? If the aims of the Center are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Is there a clear integration of the Center components -Cores and Projects- to an overarching theme that integrates and focuses the Center, as well as the presence of an essential relationship of each research project and core component to the theme?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the Center? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI , do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Does the Center Director have the ability to lead a scientific program as documented by scientific achievements, productivity, stature in a relevant field, and planned activities? Does the Center Director have the ability to lead administrative and operational aspects of the Center, as noted by administrative skills, achievements, and planned activities and is there evidence of ability to develop or maintain a role for the Center as a national resource? Is there adequate commitment of time and effort for the research and administrative functions of the Center? As a group, are Research Project and Core investigators well suited to the projects? Is there evidence of multidisciplinary backgrounds and interests?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the Center? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?
If the Center involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed? Does the application clearly demonstrate, in a diagram, the feasibility of the organizational structure? Does the organizational structure have clear lines of authority that allow for efficient and cost-effective management and allocation of funds, as well as leverage of resources to enable additional or future work? Are the organizational and administrative structure and support capable of creating thematic integration that is conducive to research, synergy, and joint planning? Is there an operational programmatic structure that effectively promotes productive scientific interactions, cross fertilization, and takes maximum advantage of the applicant institution's drug abuse research capacity?
Is a process in place for long range planning and evaluation of Center activities? Is there an appropriate, fully described internal process that allows for priority setting and decision making to sustain the Center? Is there appropriate specification of criteria and processes for determining and sustaining individual participation in the Center based on productivity, research direction, and overall contribution? Are there arrangements for internal quality control of research, publications, and grant applications? Does the outside advisory structure have the capacity to provide appropriate and objective advice and evaluation? Are there adequate plans for recruitment, education, and supervision of staff?
Are there sufficient interactions and linkages of components to each other, to show that the impact of a coordinated Center goes beyond the impact of individual research projects? Does the approach taken for Center activities make use of a depth and breadth of expertise and experience not normally present in an individual research project grant?
Do the core components as a group contribute resources that enhance cost-effectiveness and quality control in resource utilization?
Do the Center’s activities involve different scientific disciplines or sub-disciplines and demonstrate substantial interaction among scientists from different disciplines or sub-disciplines and different perspectives?
Will the proposed career development and mentoring activities provide high quality, appropriate research career development and are they likely to be effective in attracting and involving junior investigators and students who show potential for significant future contributions and independent research careers in the work of the Center? Are the objectives, design and direction of the proposed career development and mentoring likely to ensure effective career enhancement? Does the program provide appropriate inter- or multidisciplinary research training opportunities? Are the proposed professional development and mentoring activities likely to foster the careers of new investigators?
Do the proposed educational and outreach activities to drug abuse research communities, organizations, general public, and/or policy makers support the ability of the Center to be a national resource?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Are there plans for development and maintenance of an environment that promotes the conduct of the highest quality of research, innovation, and leadership? Are there appropriate and adequate facilities for administrative, research, and shared resources, including a clearly identifiable physical location for the Center, which assures necessary functions can occur? Do the facilities indicate the Center is, or would soon be, a national scientific research resource?
Is there adequate institutional support; for example, letters of support, space and resources to be allocated from the applicant institution, substantial commitment to the Center and appreciation of its goals and role in public health, especially in the drug abuse and addiction research field?
Does the environment provide adequate high quality data analytic capacity, data base facilities, coordination, and data resources? As needed, are there provisions for shared laboratory resources, high quality laboratory space, and clinical facilities?
As applicable for the Center proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed Center involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Renewals, the committee will consider the progress made in the last funding period.
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the center. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the Center proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Not Applicable
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genomic Data Sharing Plan .
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the Core to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the Center proposed).
Reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. A Core does not need to be strong in all categories to be judged likely to have major impact. For example, a Core that by its nature is not innovative may be essential to promote activities in the Center.
Significance
Does the Core Component address important scientific and administrative activities of the Center? If the aims of the Core are achieved, how well will it contribute to the function of the Center? How will successful completion of the aims contribute to support of the concepts, methods, technologies, treatments, services, or preventative interventions carried out in other components of the Center? Is there adequate justification for this Core activity being conducted within a Center structure?
Investigator(s)
Are the Core Director, the collaborators, and other researchers well suited to the Core? If the Core Director is an Early Stage Investigator, New Investigator, or a researcher in the early stages of an independent career, does he/she have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?
Innovation
Does the Core utilize novel theoretical concepts, approaches or methodologies, instrumentation, or interventions in support of the Center? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and plans for
day to day management well-reasoned and appropriate to accomplish the support
of Center activities? Are potential problems, alternative strategies, and
benchmarks for success presented? Are the arrangements and organizational
structure adequately developed, well integrated, well-reasoned, and integrated
with multiple other components of the Center? Is the justification for the need
for Core services or resources clearly stated and are there appropriate plans
for resource allocation?
If the Core activity involves clinical research, are the plans for 1)
protection of human subjects from research risks, and 2) inclusion of
minorities and members of both sexes/genders, as well as the inclusion of children,
justified in terms of the scientific goals and research strategy proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the Core proposed? Will the Core benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Children
When the proposed Center involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the Core to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the Center proposed).
Reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. A Pilot Project Core does not need to be strong in all categories to be judged likely to have major impact. For example, a Pilot Project Core that by its nature is not innovative may be essential to promote activities in the Center.
Significance
Do the pilot research topics address an important problem or a critical barrier to progress in the field and are they consistent with the overall goals of the Center? If the aims of the project(s) are achieved, how will they improve scientific knowledge, technical capability, and/or clinical practice? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Do the projects have the potential to develop into full-scale independent projects?
Investigator(s)
Does the Core Director have the qualifications to lead this component? In the individual pilot projects, are the project leaders, their collaborators, and other researchers well suited to the projects? If they are Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?
Innovation
Do the proposed pilot projects or the process for generating new pilot projects challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses
for proposed pilot projects and the process for managing the pilot project core
well-reasoned and appropriate to accomplish the specific aims of the projects?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be managed?
Are there adequate plans to evaluate progress of ongoing pilot projects and to
generate and monitor new projects? Are monitoring, oversight procedures and
continuation decisions explained? Do the pilot projects chosen reflect that an
appropriate process for selection of pilot projects is in place?
If the pilot projects involve clinical research, are the plans for 1) protection
of human subjects from research risks, and 2) inclusion of minorities and
members of both sexes/genders, as well as the inclusion of children, justified
in terms of the scientific goals and research strategy proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the pilot project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for Pilot Project Core proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Children
When the proposed Center involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. A Research Project Component does not need to be strong in all categories to be judged likely to have major impact. For example, a Research Project Component that by its nature is not innovative may be essential to promote activities in the Center.
Significance
Does the research project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? Will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Is the research project well integrated into the overarching theme of the Center and interactive with other research components or cores?
Investigator(s)
Are the Research Project Director, the collaborators, and other researchers well suited to the research project and do they commit sufficient time to the research project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?
Innovation
Does the research project challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the research project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be managed?
If the research project involves clinical research, are the plans for 1)
protection of human subjects from research risks, and 2) inclusion of
minorities and members of both sexes/genders, as well as the inclusion of children,
justified in terms of the scientific goals and research strategy proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the research project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the research project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Children
When the proposed Center involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the National Institute on Drug Abuse in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Drug Abuse. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
To promote information sharing, to facilitate collaboration, and to address issues of common concern among NIDA research Centers, NIDA may ask Center Directors to participate in meetings on an as-needed basis.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Awardee-selected projects that involve clinical trials or studies involving greater than minimal risk to human subjects require prior approval by NIH prior to initiation.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Not Applicable
When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
eRA Commons Help Desk (Questions regarding eRA Commons
registration, submitting and tracking an application, documenting system
problems that threaten submission by the due date, post submission issues)
Finding Help Online: https://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Grants.gov Customer Support (Questions
regarding Grants.gov registration and submission, downloading forms and
application packages)
Contact Center Telephone: 800-518-4726
Email: [email protected]
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Email: [email protected] (preferred method of contact)
Telephone: 301-945-7573
Kevin Walton, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-0762
Email: [email protected]
Meyer D. Glantz, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: [email protected]
Roger Little, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1316
Email: [email protected]
Steven Grant, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-4877
Email: [email protected]
Mark Swieter, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone:301-827-5844
Email: [email protected]
Cheryl Nathaniel
National Institute on Drug Abuse (NIDA)
Telephone: 202-526-0108
Email: [email protected]
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.